TABLE 1

Summary of results for simulated EBOV specimen (item 1) included in three PTs and overall performance of participating laboratories

DateParticipantEBOVaEBOV-specific targetsb
NPGPL
April 20141YDD
2
3
4YDD
5
6
7
8
9
10YD
November 20141YDD
2YDcD
3NdND
4YDcDDc
5
6
7YDDD
8
9
10YDDD
March 20161Ye
2YDD
3YD
4YDcDDc
5YDD
6YD
7
8YDDD
9YDcDc
10YDDD
  • a Y, present; N, not present.

  • b D, target detected; ND, target not detected; —, target not tested.

  • c A result from a second EBOV-specific NAT assay was reported.

  • d The laboratory reported the use of RealStar Ebolavirus RT-PCR kit 1.0 (Altona Diagnostics GmbH; authorized by the U.S. FDA through the issue of the Emergency Use Authorization). Item 2 in the same proficiency testing, which did not contain any genetic material, was reported as having EBOV-specific targets detected.

  • e The laboratory reported the use of a kit (as supplied by the U.S. CDC; the gene target was undisclosed).